Newly diagnosed COVID-19 patients who have not yet received treatment may be eligible to participate in a randomized clinical research study at Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Hospital in New Brunswick, and University Hospital in Newark.  The research study is examining the drugs hydroxylchloroquine and the antibiotic azithromycin.  The purpose of this research is to determine if the combined drugs work better then hydroxychloroquine alone when treating COVID-19 positive patients.  To see if you are eligible to participate, contact Rutgers Cancer Institute’s Office of Human Research Services at 732-235-7356 or email